Application of molecular biology in prognosis evaluation of myelodysplastic syndromes

Myelodysplastic syndromes are a group of heterogeneous myeloid tumors and the prognosis is affected by a variety of factors. The pathophysiology of myelodysplastic syndromes (MDS) is unclear. Recent studies have shown that MDS patients have extensive genetic abnormalities. With the development of new genome sequencing technology, abnormal genes can be found in about 80% of MDS patients. These molecular biological abnormalities have the prospect of guiding targeted therapy and disease surveillance, and can give a hope for the individualized management of heterogeneous hematological malignancies. Here, the prognostic factors of MDS, especially for MDS molecular biology in recent years have been reviewed. Key words: Myelodysplastic syndromes; Molecular biology; Prognosis; Review